| Description | Wee1 Inhibitor I is an ATP-binding site-targeting Wee1 inhibitor. |
| Target activity | Wee1:0.011 μM (IC50) |
| Synonyms | Wee1-Inhibitor-I, Wee1 Inhibitor-I, Wee1 Inhibitor I, Wee1-Inhibitor I |
| molecular weight | 362.77 |
| Molecular formula | C20H11ClN2O3 |
| CAS | 622855-37-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Schmidt M, Rohe A, Platzer C, Najjar A, Erdmann F, Sippl W. Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases. Molecules. 2017 Nov 23;22(12). pii: E2045. doi: 10.3390/molecules22122045. Review. PubMed PMID: 29168755. 2. Mills CC, Kolb EA, Sampson VB. Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer. Cancer Res. 2017 Dec 1;77(23):6489-6498. doi: 10.1158/0008-5472.CAN-17-2066. Epub 2017 Nov 2. Review. PubMed PMID: 29097609; PubMed Central PMCID: PMC5712276. 3. Brandsma I, Fleuren EDG, Williamson CT, Lord CJ. Directing the use of DDR kinase inhibitors in cancer treatment. Expert Opin Investig Drugs. 2017 Dec;26(12):1341-1355. doi: 10.1080/13543784.2017.1389895. Epub 2017 Oct 14. Review. PubMed PMID: 28984489. 4. Visconti R, Grieco D. Fighting tubulin-targeting anticancer drug toxicity and resistance. Endocr Relat Cancer. 2017 Sep;24(9):T107-T117. doi: 10.1530/ERC-17-0120. Review. PubMed PMID: 28808045. |